DocMorris AG (0RRB) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone, and welcome to our Q126 trading update. I'm Walter Hess, the CEO, and I'm joined today by our CFO, Danielle Wüst. In line with what we announced at the Fulia conference, we will provide transparent quarterly insights into our path to EBITDA breakeven, which is why we are hosting today's call. Just a few weeks ago, During our full year 25 results, we outlined our strategic evolution from an online pharmacy player to the leading digital and AI health platform, the engine for our profitable expansion at scale. Today, we will show you the facts that validate our successful development. Let's move straight to the Q1 highlights on the next slide. to demonstrate how well this engine is now accelerating. Overall, we achieved a strong revenue growth of 10.7% year over year. Our RX business showed outstanding momentum with a 30.4% growth year over year, alongside a strong 7.6% sequential growth compared to the previous quarter. The growth was fueled by accelerating month over month with a remarkable uptick in March, which also continues in April. Our high-margin digital services business continues to scale rapidly, achieving an impressive 63.1% growth rate while consistently increasing margins. In Q126, we successfully expanded our ecosystem platform, growing our active customer base by 1 million year-over-year, whereas 0.4 million in Q126 to a total of 12.6 million, which is a great achievement. And most importantly, and as you know, our main priority, we improved our adjusted EBITDA by 10 million Swiss francs year-over-year, to minus six million, proving we are on track to achieve our break-even target in the course of 2026. Let's move to slide number five now. The 30.4% year-over-year Rx growth clearly proves that our strategy to capture the potentia...